Ophthalmology
Volume 118, Issue 1 , Pages 41-46 , January 2011

Moscow Eye Microsurgery Complex in Russia Keratoprosthesis in Beijing

  • Yifei Huang, MD, PhD

      Affiliations

    • Yifei Huang and Jifeng Yu contributed equally to this work.
    • Corresponding Author InformationCorrespondence: Yifei Huang, MD, PhD, Department of Ophthalmology, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, China
    • ,
  • Jifeng Yu, MD

      Affiliations

    • Yifei Huang and Jifeng Yu contributed equally to this work.
    • ,
  • Li Liu
    • ,
  • Gaiping Du, MD
    • ,
  • Jing Song, MD
    • ,
  • Huiling Guo, MD

Received 23 September 2009 ,Revised 1 May 2010 ,Accepted 21 May 2010.

References 

  1. Barber JC. Keratoprosthesis: past and present. Int Ophthalmol Clin. 1988;28:103–109
  2. Hicks CR, Fitton JH, Chirila TV, et al. Keratoprostheses: advancing toward a true artificial cornea. Surv Ophthalmol. 1997;42:175–189
  3. Ma JJ, Graney JM, Dohlman CH. Repeat penetrating keratoplasty versus the Boston keratoprosthesis in graft failure. Int Ophthalmol Clin. 2005;45:49–59
  4. Aquavella JV, Gearinger MD, Akpek EK, McCormick GJ. Pediatric keratoprosthesis. Ophthalmology. 2007;114:989–994
  5. Bersudsky V, Blum-Hareuveni T, Rehany U, Rumelt S. The profile of repeated corneal transplantation. Ophthalmology. 2001;108:461–469
  6. Alvarenga LS, Mannis MJ, Brandt JD, et al. The long-term results of keratoplasty in eyes with a glaucoma drainage device. Am J Ophthalmol. 2004;138:200–205
  7. Yaghouti F, Nouri M, Abad JC, et al. Keratoprosthesis: preoperative prognostic categories. Cornea. 2001;20:19–23
  8. Aldave AJ, Kamal KM, Vo RC, Yu F. The Boston type I keratoprosthesis: improving outcomes and expanding indications. Ophthalmology. 2009;116:640–651
  9. Zerbe BL, Belin MW, Ciolino JB Boston Type 1 Keratoprosthesis Study Group. Results from the multicenter Boston Type 1 keratoprosthesis study. Ophthalmology. 2006;113:1779–1784
  10. Hicks CR, Crawford GJ, Tan DT, et al. AlphaCor cases: comparative outcomes. Cornea. 2003;22:583–590
  11. Hicks CR, Hamilton S. Retroprosthetic membranes in AlphaCor patients: risk factors and prevention. Cornea. 2005;24:692–698
  12. Bradley JC, Hernandez EG, Schwab IR, Mannis MJ. Boston type 1 keratoprosthesis: the University of California Davis experience. Cornea. 2009;28:321–327
  13. Ray S, Khan BF, Dohlman CH, D'Amico DJ. Management of vitreoretinal complications in eyes with permanent keratoprosthesis. Arch Ophthalmol. 2002;120:559–566
  14. Aquavella JV, Qian Y, McCormick GJ, Palakuru JR. Keratoprosthesis: the Dohlman-Doane device. Am J Ophthalmol. 2005;140:1032–1038
  15. Nouri M, Durand ML, Dohlman CH. Sudden reversible vitritis after keratoprosthesis: an immune phenomenon?. Cornea. 2005;24:915–919
  16. Nouri M, Terada H, Alfonso EC, et al. Endophthalmitis after keratoprosthesis: incidence, bacterial causes, and risk factors. Arch Ophthalmol. 2001;119:484–489

 Manuscript no. 2009-1321.

 Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

PII: S0161-6420(10)00561-0

doi: 10.1016/j.ophtha.2010.05.019

Ophthalmology
Volume 118, Issue 1 , Pages 41-46 , January 2011

Article Tools

* Image Usage & Resolution